India Amends Drugs Rules, 1945 to Include Advanced Cell and Gene Therapies Under Central Licensing

Key Facts

• The Drugs Rules, 1945 were amended on 2 July 2026, with the amendment notified on 29 June 2026 as the Drugs (Eighth Amendment) Rules, 2026.
• The amendment brings advanced cell and gene therapies under the Centrally License Approving Authority (CLAA) framework.
• Included products are cell or stem cell-derived products (e.g., CAR-T cell therapies), gene therapeutic products (such as gene replacement and gene editing treatments), and xenografts (animal tissue-derived products like heart valves used in cardiology and orthopaedics).
• The Drugs Rules, 1945, are framed under the Drugs and Cosmetics Act, 1940, governing import, manufacture, distribution and sale of drugs in India.
• The CLAA framework ensures joint oversight by Central and State Licensing Authorities, enabling uniform regulatory standards across India.
• Prior to the amendment, the CLAA framework covered vaccines, large volume parenterals (>100 ml IV solutions), and r-DNA based medicines.
• The Ministry of Health and Family Welfare issued a Gazette notification (G.S.R. 758(E)) on 16 October 2025 inviting public comments before finalizing the amendment.
• The amendment addresses the need for enhanced regulatory scrutiny for these complex, specialized, and rapidly evolving medical technologies to ensure patient safety and quality control.

Background & Context

The Drugs Rules, 1945 serve as procedural guidelines under the Drugs and Cosmetics Act, 1940, covering aspects such as licensing, inspection, testing, labelling, and quality control of pharmaceutical products in India. The rapid growth of advanced therapies—including stem cell-based regenerative treatment, CAR-T immunotherapies for blood cancers, gene replacement and editing therapies for genetic disorders and cancers, and xenografts—has necessitated regulatory updates to maintain patient safety and uphold product quality. The CLAA framework supplements existing drug regulations by providing centralized oversight, particularly for biologically complex and critical drugs, to ensure uniform application of standards across all states. Incorporating advanced therapies in the CLAA allows for harmonized regulation as well as faster innovation and adoption within India's healthcare and life sciences sectors.

Why This Matters for Exams / Exam Relevance

This amendment exemplifies evolving healthcare and pharmaceutical regulations in India, a key topic under contemporary governance, public health, and science and technology programs. Understanding the Drugs and Cosmetics Act, its rules, and the CLAA framework is pivotal for exams covering Indian regulatory systems and healthcare advancements. Additionally, knowledge of advanced therapies—CAR-T cells, gene therapeutics, and xenografts—is important for current affairs and biotechnology segments in competitive exams.

Points to Remember

• The Drugs (Eighth Amendment) Rules, 2026 were notified on 29 June 2026 and came into effect on 2 July 2026.
• Advanced cell and gene therapies now require central licensing approval under the CLAA framework alongside state authorities.
• CAR-T cell therapy is a chimeric antigen receptor T-cell immunotherapy used in treatment of blood cancers such as leukemias and lymphomas.
• Gene therapeutic products include gene replacement therapies and gene editing products for genetic diseases and various cancers.
• Xenografts are animal tissue-derived transplants (e.g., heart valves) used in human medicine, particularly cardiology and orthopaedics.
• The amendment aims to maintain a uniform regulatory standard across India, ensuring patient safety while fostering scientific innovation.
• Public consultation was conducted before finalizing the amendment, reflecting a participatory regulatory process.